A Bermudian genetics laboratory has helped to develop tests that enable users of medicinal cannabis to understand how their bodies react to cannabinoids.

The simple, at-home tests have been developed by CariGenetics in partnership with US scientists and have been described as “a game-changer” in the safe administering of medicinal cannabis.

Carika Weldon, the founder and chief executive of CariGenetics, said that cannabinoids were a diverse class of synthetic as well as naturally occurring chemical compounds, and patients responded to them differently depending on their genetic make-up.

At a press conference announcing the development on Wednesday, Dr Weldon said: “The way our nervous systems and body react to cannabinoids is dependent on your genes.

“For example, a significant interaction was found between lifetime frequency of cannabis use and a variant in the DRD2 gene on psychosis risk.”

According to Dr Weldon, the cannabis DNA test — 4Twenty — was designed to help individuals understand how their bodies respond to cannabinoids, offering detailed information on genetic predispositions and personalised dosing for safe cannabis use.

A second test — VividlyYou — is designed to help individuals understand how they respond to nine psychedelics, providing valuable insights for safe and effective use.

Dr Weldon said: “4Twenty reveals 13 genetic traits that can show you how to avoid unwanted side-effects and promote health benefits, including the genetic risk of cannabis dependence, psychosis risk from cannabis use and inherent pain threshold.

“Your results will decode the information in your genes to recommend personalised dosing for medical use, removing the guesswork. Our report details metabolism and dosing, pain management, sleep, side-effects and anxiety and stress to ensure your experience is optimal and safe.”

Dr Weldon said the kits were the first of their kind to be offered in the Caribbean and will “fill a data void about how these substances affect our distinct genetic make-up in the region”.

The announcement was backed by the Bermuda Cannabis Association, which called on the Government to update legislation on medicinal cannabis.

Medicinal cannabis was made legal in 2016, but only products having a THC content of less than 1 per cent are permitted.

Kim Caisey, cofounder of the BCA, said: “These products represent a significant step forward in ensuring that individuals can make an informed decision about their cannabis use based on their genetic profile.

“We are dedicated to advancing the cannabis industry in Bermuda by assisting the Government with policy development, supporting businesses with regulation and compliance, and educating the community about the benefits and safe use of cannabis.

“Our mission is to ensure that Bermuda has a robust and well-regulated cannabis industry that prioritises safety for all.

“We are calling on the Government to make cannabis policy a priority. The time has come for Bermuda to embrace the potential of cannabis for medical, economic and social benefits.

“By working together, we can create a framework that ensures product safety, supports local businesses and educates the public. We are collaborating with experts to draft comprehensive legislation that emphasises product safety and testing.”

Cofounder Rikai Robinson agreed.

He said: “We are thrilled to partner with CariGenetics, who have developed two innovative products that will help individuals understand the genetic predispositions and their responses to cannabis and psychedelics.

“These products are a game-changer in promoting safe cannabis use.

“Education is the cornerstone of our mission. It is crucial for the community to understand the benefits and potential risks of cannabis use.

“Medical cannabis provides relief for various conditions including chronic pain, anxiety and epilepsy.

“Access to safe and regulated medical cannabis can significantly improve the quality of life for our patients. Understanding the different effects of cannabis on various body types is essential, as genetics play a significant role in how individuals respond to cannabis.

“It’s important for people to know how their bodies will react to different substances and that is where genetic testing comes in — understanding your genetic make-up, you can make more informed decisions about cannabis use, minimising risk and maximising benefits.”